Investors Urged to Join Securities Fraud Class Action Against ADMA

The complaint filed by Schall, Brown & Schwartz LLP alleges that ADMA Biologics misled the market through a series of deceptive acts. According to the filing, the company failed to disclose a related-party transaction, employed channel stuffing to artificially inflate revenue figures, and neglected to maintain necessary internal financial controls. These actions allegedly caused investors to suffer damages once the true state of the company’s operations surfaced.

Shareholders seeking to participate in the litigation or discuss their legal standing may contact Brian Schall or David Schwartz at the firm’s Los Angeles office. While the class has not yet been certified by the court, those who held shares during the specified period are eligible to pursue recovery for their losses. Participation does not require an immediate appointment as lead plaintiff, and investors who choose not to act remain absent class members until the court grants certification.